Colorectal cancer organoid culture kit

Through the use of the colorectal cancer organoid culture kit, colorectal cancer organoids are cultured in a directional manner and drug screening is carried out, which solves the treatment problems caused by difficult and rare tumors and tumor heterogeneity in the existing technology, and realizes a personalized treatment plan. Selection and maintenance of tumor immune components reduce treatment costs and improve trial success rates.

CN118909946AInactive Publication Date: 2024-11-08NEO ANTIGEN MEDICAL TECH(SHENZHEN) CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411182563.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively deal with difficult and rare tumors, primary or secondary drug resistance, no target mutations found to cause discomfort in targeted drugs, and tumor heterogeneity, and the same drug efficacy is not effective. personalized medication regimens lead to high treatment costs and low trial success rates.

Method used

Provide a colorectal cancer organoid culture kit, through the combination of improved DMEM/F12 culture medium and specific additives, the colorectal cancer organoids are targeted, and the successful cultivation of organoids are used for drug screening, and the most suitable personality is selected. Chemical medication regimens extend patient survival and reduce treatment costs.

Benefits of technology

It has achieved the choice of personalized treatment plans for difficult and rare tumors, prolonged patient survival, reduced the number of drug tests and total treatment costs, and effectively maintained the tumor immune components in colorectal cancer organoids.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909946A_ABST
    Figure CN118909946A_ABST
Patent Text Reader

Abstract

The invention discloses a colorectal cancer organoid culture kit which comprises an organoid culture medium A and an additive component B. The organoid culture medium A comprises an improved DMEM / F12 culture medium, penicillin streptomycin, HEPES, L-alanyl-L-glutamine, an N2 additive and a B27 additive. And the additive component B comprises normal saline, a sulfobutyl ether beta-cyclodextrin derivative, gastrin 1, A83-01, SB202190, Y-27632, a recombinant human Wnt-3a, N-acetyl-L-cysteine, a recombinant human epidermal growth factor, a recombinant human R-spondin protein and a recombinant human Noggin protein. The kit disclosed by the invention can be used for directionally culturing colorectal cancer organoid, and colorectal cancer drug screening can be carried out by utilizing the successfully cultured organoid.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a colorectal cancer organoid culture kit. Background Art

[0002] Organoids are made of stem cells or organ progenitor cells. After in vitro culture, they can undergo cell differentiation and lineage orientation, that is, self-assemble into a cell group of organ-like structures, which can largely simulate the genetic characteristics and epigenetic characteristics of the target tissue or organ, and fully retain the immunological and histological characteristics of the human body. The cell clusters formed can simulate the characteristics of tumors and tumor cell heterogeneity in vivo. The establishment of this technology has provided a reliable model for cancer research and treatment, especially opened up new horizons for personalized cancer treatment. Compared with traditional tumor research models, tumor organoids can simulate the structure and function of tumors in vivo to the greatest extent, can intuitively show the process of tumor growth, and can reflect individual differences in patients. It is an intuitive, reliable, efficient and ethically controversial organ-level research system, which is more suitable for in vitro tumor biology and treatment-related research.

[0003] The application of organoids in the commercial market is mainly in the development of new drugs and the expansion of indications. Currently, about 85% of preclinical drugs fail to develop after entering clinical trials, resulting in huge costs and losses. Organoids can be used for more comprehensive preclinical efficacy evaluation, which is of great value in reducing the cost of later drug development. In the development of anti-tumor drugs, PDO can reflect tumor heterogeneity at high throughput and low cost, effectively making up for the shortcomings of PDX animal models. Organoids are used as "patient substitutes" in Phase 0 "quasi-clinical trials" to improve the success rate of clinical trials. Summary of the invention

[0004] In view of this, the purpose of the present invention is to provide a colorectal cancer organoid culture kit for the treatment and in vitro culture of human colorectal cancer. The cultured cells are only used for clinical in vitro diagnosis purposes and are not used for cell therapy, cell transfusion, assisted reproduction and other therapeutic purposes.

[0005] In order to achieve the above object, the present invention provides the following technical solutions:

[0006] A colorectal cancer organoid culture kit, comprising an organoid culture medium A, an additive component B,

[0007] The organoid culture medium A includes the following components: modified DMEM / F12 culture medium, 100× penicillin-streptomycin, 1M HEPES, 200mM L-alanyl-L-glutamine, 100× N2 supplement, 50× B27 supplement;

[0008] The additive component B includes the following components: normal saline, 20% sulfobutyl ether β-cyclodextrin derivative, 10uM gastrin 1, 1mM A83-01, 5mM SB202190, 10.11mM Y-27632, 600μg / ml recombinant human Wnt-3a, 200mM N-acetyl-L-cysteine, 50ug / mL recombinant human epidermal growth factor, 100ug / ml recombinant human R-spondin protein, and 50ug / ml recombinant human Noggin protein.

[0009] Preferably, the present invention further comprises matrix glue, wherein the matrix glue is an enzymatic hydrolysate of animal rat tail.

[0010] Preferably, the present invention further comprises a digestion solution and a sample preservation solution;

[0011] The digestion solution was prepared with Hank's balanced salt solution, including the following components: 3 g / L type IV collagenase, 1 g / L hyaluronidase, 0.2 g / L gentamicin sulfate, 10.11 mM Y-27632;

[0012] The sample preservation solution is prepared with DMEM, including the following components: 0.5 g / L ampicillin, 0.5 g / L streptomycin, 0.1 g / L gentamicin sulfate, 2 mg / L amphotericin B, 10.11 mM Y-27632, and 10 mL / L fetal bovine serum.

[0013] Preferably, the pH value of the organoid culture medium A is 7.0-7.2.

[0014] Preferably, the method for culturing colorectal cancer organoids of the present invention comprises the following steps:

[0015] (1) Place the sample in a tissue sampling bottle containing sample preservation solution, quickly transport it to a clean laboratory for tissue processing and cell separation, take photos and register the information;

[0016] (2) Prepare several culture dishes and add pre-cooled organoid culture medium A at 4 degrees Celsius for later use;

[0017] (3) Disinfect the sampling bottle, place the sample in a culture dish, rinse three times with organoid culture medium A, and cut the sample into tissue blocks with a volume of approximately 1 to 3 mm3 using sterilized ophthalmic scissors or a scalpel;

[0018] (4) After adding digestion solution and shaking digestion at 37°C, add DMEM medium to terminate digestion;

[0019] (5) After filtering with a mesh, centrifuge and remove the supernatant, add DMEM medium and centrifuge again;

[0020] (6) Add Matrigel to resuspend and plate on ice;

[0021] (7) Place the plate in a 37°C incubator for 10-15 min to gel, then add complete organoid culture medium for culture.

[0022] Preferably, the matrix gel is diluted with the organoid culture medium A before use, and the dilution concentration is the organoid culture medium A: matrix gel = 1:4.

[0023] Preferably, in the present invention, the additive component B is added to the organoid culture medium A to form a complete organoid culture medium for use, and the volume ratio of A:B is 200:1.

[0024] Preferably, the method for drug screening of the present invention comprises the following steps:

[0025] (1) Carefully aspirate the culture medium in the 96-well plate;

[0026] (2) Add 150 μl of digestion solution to each well of a 96-well plate and mix the gel thoroughly;

[0027] (3) Aspirate the digestion fluid and place it in a 15 ml centrifuge tube;

[0028] (4) Place the 15 ml centrifuge tube in a 37°C shaker for 20 min at 100 RPM;

[0029] (5) diluting the Matrigel digestion solution with DMEM / F12 medium containing 2% fetal bovine serum;

[0030] (6) Centrifuge at 300 g for 3 min to obtain the lower cell pellet;

[0031] (7) If there is colloid in the precipitate, remove the upper solution and repeat steps 2-5;

[0032] (8) After gelation, the organoids were centrifuged at 300 g for 3 min, the supernatant was removed, the organoids were washed with PBS, the cells were resuspended in organoid culture medium, and the organoids were counted to 6000 cells / ml;

[0033] (9) Organoids were seeded in 96-well plates, and drugs were added to each group of cells at corresponding concentrations of 0 μM, 5 μM, 10 μM, 25 μM, and 50 μM, with a total volume of 120 μl;

[0034] (10) After 48 h of incubation in a carbon dioxide incubator, 100 μl of CellTiter-Lumi TM PlusII;

[0035] (11) Place the 96-well plate on a shaker at 37°C for 2 min to lyse the cells;

[0036] (12) After lysis is completed, place the plate at room temperature for 10 min;

[0037] (13) Detect using an ELISA reader, record the luminescence value, and calculate the IC50.

[0038] Preferably, the drug is 5-fluorouracil, oxaliplatin, docetaxel, raltitrexed, regorafenib, bevacizumab or toripalimab.

[0039] The beneficial effects of the present invention are:

[0040] In view of the problems such as the lack of standard medication regimens for difficult and rare tumors, primary or secondary drug resistance, the lack of target mutations leading to the incompatibility of targeted drugs, and the different efficacy of the same drugs due to tumor heterogeneity, the kit of the present invention can be used to culture colorectal cancer organoids in a targeted manner, and the successfully cultured organoids can be used for colorectal cancer drug screening, thereby seizing the key window period for tumor treatment and selecting the most appropriate personalized medication regimen, ultimately achieving the purpose of extending patient survival, reducing the number of drug trials, and saving total treatment costs, without the need for additional sampling. Through the implementation of the present invention, the tumor immune components in colorectal cancer organoids can also be effectively maintained. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] In order to make the purpose, technical solution and beneficial effects of the present invention clearer, the present invention provides the following drawings for illustration:

[0042] Figure 1 The cell status on day 0 of colorectal cancer organoid culture;

[0043] Figure 2 This is the cell status of colorectal cancer organoid culture on day 11;

[0044] Figure 3 Results of the drug screening for oxaliplatin;

[0045] Figure 4 Results of drug screening for raltitrexed;

[0046] Figure 5 Screening results for Regorafenib drug;

[0047] Figure 6 This is the result of bevacizumab drug screening;

[0048] Figure 7 This is the result of drug screening for Teplizumab; DETAILED DESCRIPTION

[0049] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0050] Example 1. Preparation of a colorectal cancer organoid culture kit

[0051] (1) Organoid Culture Medium A

[0052] To the modified DMEM / F12 medium (Advanced DMEM / F12), 100× penicillin-streptomycin (purchased from Procell, catalog number PB180120), 1M HEPES (purchased from Procell, catalog number PB180325), 200mM L-alanyl-L-glutamine (GlutaMAX, purchased from GIBCO, catalog number 35050061), 100×N2 additive (purchased from Invitrogen, catalog number 17502001), and 50×B27 additive (purchased from Invitrogen, catalog number 17504044) were added in sequence, mixed, stirred at 100 rpm / min for 10 min, filtered through a 0.2 μm filter membrane, and packaged at 100 mL / bottle.

[0053] (2) Additive component B

[0054] Prepared with physiological saline, additive component B, 0.9g sodium chloride, dissolved in ddH2O and fixed to 100mL, a clear and transparent physiological saline solution can be obtained; 20% sulfobutyl ether β-cyclodextrin derivative (2g SBE-β-CD) powder was fixed to 10mL of physiological saline and completely dissolved until clear and transparent; 10uM gastrin 1 (gastrin I, purchased from MCE, product number HY-P1097), 1mM A83-01 (purchased from MCE, product number HY-10432), 5mM SSB202190 (purchased from MCE, product number HY-10295), 10.11mM Y-27632 (purchased from MCE, product number HY-10071), 600μg / ml recombinant human Wnt-3a (purchased from R&D Systems, product number 5036-WN), 200mM N-acetyl-L-cysteine ​​(purchased from AbMole, catalog number M5385), 50ug / mL recombinant human epidermal growth factor (purchased from R&D Systems, catalog number 236-EG-200), 100ug / ml recombinant human R-spondin protein (purchased from R&D Systems, catalog number 4645-RS-025), 50ug / ml recombinant human Noggin protein (purchased from R&D Systems, catalog number 6057-NG-100), shake and mix well, filter with 0.2μm filter membrane, and package at 0.5mL / bottle.

[0055] (3) Digestive juice

[0056] The digestion solution was prepared with Hank's balanced salt solution, and 3g / L type IV collagenase (purchased from Yisheng Biotechnology, product number 40510ES76), 1g / L hyaluronidase (purchased from Yisheng Biotechnology, product number 20426ES80), 0.2g / L gentamicin sulfate (purchased from Yisheng Biotechnology, product number 60214ES08), and 10.11mM Y-27632 were added in sequence. After mixing, the mixture was stirred at 100rpm / min for 10min, filtered through a 0.2μm filter membrane, and packaged in 100mL / bottle.

[0057] (4) Sample preservation solution

[0058] The sample preservation solution was prepared with DMEM, and 0.5 g / L ampicillin (purchased from Yisheng Biological, product number 60203ES60), 0.5 g / L streptomycin (purchased from Yisheng Biological, product number 60211ES60), 0.1 g / L gentamicin sulfate (purchased from Yisheng Biological, product number 60214ES08), 2 mg / L amphotericin B (purchased from Yisheng Biological, product number 60238ES03), 10.11 mM Y-27632, and 10 mL / L fetal bovine serum (purchased from Yisheng Biological, product number 40130ES76) were added in sequence. After mixing, the solution was stirred at 100 rpm / min for 10 min, filtered through a 0.2 μm filter membrane, and packaged at 100 mL / bottle.

[0059] Example 2: Method for culturing colorectal cancer organoids

[0060] Fresh biopsy or surgical specimens must be processed within 2 hours of ex vivo sampling.

[0061] a. Place the sample in a tissue sampling bottle containing 5 ml of sample preservation solution, quickly transport it to a clean laboratory for tissue processing and cell separation, take photos and register the information;

[0062] b. Prepare several culture dishes and add pre-cooled organoid culture medium A at 4 degrees for later use;

[0063] c. Sterilize the sampling bottle, place the sample in a culture dish, rinse three times with organoid culture medium A, and cut the sample into tissue blocks of approximately 1 to 3 mm3 with sterilized ophthalmic scissors or a scalpel;

[0064] d. Add digestion solution and shake and digest at 37℃ for 10-20 minutes (observe the digestion status at any time during the digestion process);

[0065] e. Take a small amount of liquid and observe it under a microscope. After a large number of single cells or cell clusters smaller than 70 μm are observed under the microscope, add 3 times the volume of DMEM medium containing 2% serum to terminate the digestion;

[0066] f. Filter using a 100 μm pore size mesh, collect the filtrate, centrifuge at 300 g for 5 min, remove the supernatant, add DMEM medium containing 2% serum and centrifuge again;

[0067] g. Matrigel calculation: After step 6, observe the volume of tissue collected and add 25 times the volume of tissue to resuspend and plate;

[0068] (Matrigel was diluted with cell culture medium A before use, and the dilution concentration was tissue culture medium A:matrigel = 1:4)

[0069] h. Taking a 24-well cell culture plate as an example, apply 25ul of tissue matrix gel mixture to each well for plating (operate on ice); i. Place the plate in a 37°C incubator for 10-15 minutes to gel, and add complete organoid culture medium for culture;

[0070] (Add medium supplement B to organoid medium A to form complete organoid medium for use, A:B volume ratio

[0071] =200:1).

[0072] The culture results are as follows Figure 1 and Figure 2 As shown, Figure 1 The cell status of colorectal cancer organoid culture on day 0. Figure 2 The cell status of colorectal cancer organoids on day 11 of culture.

[0073] Example 3: Method for drug screening

[0074] a. Carefully aspirate the culture medium in the 96-well plate;

[0075] b. Add 150 μl of digestion solution to each well of the 96-well plate and mix the gel thoroughly;

[0076] c. Aspirate the digestion fluid and place it into a 15ml centrifuge tube;

[0077] d. Place the 15 ml centrifuge tube in a 37°C shaker for 20 min at 100 RPM;

[0078] e. Dilute the matrix gel digestion solution with DMEM / F12 medium containing 2% fetal bovine serum;

[0079] f. Centrifuge at 300 g for 3 min to obtain the lower cell pellet;

[0080] g. If there is colloid in the precipitate, aspirate the upper solution and repeat steps 2-5;

[0081] h. After gelation, centrifuge the organoids at 300g for 3 min, remove the supernatant, wash the organoids with PBS, add organoid culture medium to resuspend the cells, and count the organoids to 6000 cells / ml;

[0082] i. Organoids were seeded in 96-well plates, and drugs were added to each group of cells at corresponding concentrations of 0 μM, 5 μM, 10 μM, 25 μM, and 50 μM, with a total volume of 120 μl;

[0083] j. After culturing in a carbon dioxide incubator for 48 h, 100 μl of CellTiter-Lumi TM PlusII;

[0084] k. Place the 96-well plate on a shaker at 37°C for 2 minutes to lyse the cells;

[0085] l. After lysis is completed, place the plate at room temperature for 10 minutes;

[0086] m. Use an ELISA reader to detect, record the luminescence value, and calculate IC50.

[0087] Drug screening results such as Figures 3 to 7 As shown, Figure 3 This is the result of oxaliplatin drug screening. Figure 4 This is the result of drug screening for raltitrexed. Figure 5 The results of Regorafenib drug screening are as follows: Figure 6 This is the result of bevacizumab drug screening. Figure 7 These are the drug screening results for Teplizumab.

Claims

1. A colorectal cancer organoid culture kit, characterized in that: Includes organoid culture medium A, supplement component B, The organoid culture medium A includes the following components: modified DMEM / F12 culture medium, 100× penicillin-streptomycin, 1M HEPES, 200mM L-alanyl-L-glutamine, 100× N2 supplement, 50× B27 supplement; The additive component B includes the following components: normal saline, 20% sulfobutyl ether β-cyclodextrin derivative, 10uM gastrin 1, 1mM A83-01, 5mM SB202190, 10.11mM Y-27632, 600μg / ml recombinant human Wnt-3a, 200mM N-acetyl-L-cysteine, 50ug / mL recombinant human epidermal growth factor, 100ug / ml recombinant human R-spondin protein, and 50ug / ml recombinant human Noggin protein.

2. A colorectal cancer organoid culture kit according to claim 1, characterized in that: It also includes matrix glue, which is an enzymatic hydrolyzate of animal rat tail.

3. A colorectal cancer organoid culture kit according to claim 1, characterized in that: It also includes digestion fluid and sample preservation fluid; The digestion solution was prepared with Hank's balanced salt solution, including the following components: 3 g / L type IV collagenase, 1 g / L hyaluronidase, 0.2 g / L gentamicin sulfate, 10.11 mM Y-27632; The sample preservation solution is prepared with DMEM, including the following components: 0.5 g / L ampicillin, 0.5 g / L streptomycin, 0.1 g / L gentamicin sulfate, 2 mg / L amphotericin B, 10.11 mM Y-27632, and 10 mL / L fetal bovine serum.

4. A colorectal cancer organoid culture kit according to claim 1, characterized in that: The pH value of Organoid Medium A is 7.0-7.

2.

5. A method for culturing colorectal cancer organoids using the colorectal cancer organoid culture kit according to any one of claims 1 to 4, characterized in that: (1) Place the sample in a tissue sampling bottle containing sample preservation solution, quickly transport it to a clean laboratory for tissue processing and cell separation, take photos and register the information; (2) Prepare several culture dishes and add pre-cooled organoid culture medium A at 4 degrees Celsius for later use; (3) Disinfect the sampling bottle, place the sample in a culture dish, rinse three times with organoid culture medium A, and cut the sample into tissue blocks with a volume of approximately 1 to 3 mm3 using sterilized ophthalmic scissors or a scalpel; (4) After adding digestion solution and shaking digestion at 37°C, add DMEM medium to terminate digestion; (5) After filtering with a mesh, centrifuge and remove the supernatant, add DMEM medium and centrifuge again; (6) Add Matrigel to resuspend and plate on ice; (7) Place the plate in a 37°C incubator for 10-15 minutes to gel, then add complete organoid culture medium for culture. keep.

6. The method for culturing colorectal cancer organoids according to claim 5, characterized in that: Before use, the matrix gel was diluted with organoid culture medium A, and the dilution concentration was organoid culture medium A: matrix gel = 1:

4.

7. The method for culturing colorectal cancer organoids according to claim 5, characterized in that: Add supplement component B to organoid culture medium A to form a complete organoid culture medium for use, with a volume ratio of A:B = 200:

1.

8. A method for drug screening, characterized in that: The intestinal cancer organoid is obtained by the method according to any one of claims 5 to 7, and the drug screening method comprises the following steps: (1) Carefully aspirate the culture medium in the 96-well plate; (2) Add 150 μl of digestion solution to each well of a 96-well plate and mix the gel thoroughly; (3) Aspirate the digestion fluid and place it in a 15 ml centrifuge tube; (4) Place the 15 ml centrifuge tube in a 37°C shaker for 20 min at 100 RPM; (5) diluting the Matrigel digestion solution with DMEM / F12 medium containing 2% fetal bovine serum; (6) Centrifuge at 300 g for 3 min to obtain the lower cell pellet; (7) If there is colloid in the precipitate, remove the upper solution and repeat steps 2-5; (8) After gelation, the organoids were centrifuged at 300 g for 3 min, the supernatant was removed, the organoids were washed with PBS, the cells were resuspended in organoid culture medium, and the organoids were counted to 6000 cells / ml; (9) Organoids were seeded in 96-well plates, and drugs were added to each group of cells at corresponding concentrations of 0 μM, 5 μM, 10 μM, 25 μM, and 50 μM, with a total volume of 120 μl; (10) After 48 h of incubation in a CO2 incubator, 100 μl of CellTiter-Lumi TM PlusII; (11) Place the 96-well plate on a shaker at 37°C for 2 min to lyse the cells; (12) After lysis is completed, place the plate at room temperature for 10 min; (13) Detect using an ELISA reader, record the luminescence value, and calculate the IC50.

9. The method for drug screening according to claim 8, characterized in that: The drugs are 5-fluorouracil, oxaliplatin, docetaxel, raltitrexed, regorafenib, bevacizumab or toripalimab.

Citation Information

Cited By

  • Auto-specific colorectal cancer composite antigen as well as preparation method and application thereof

    CN121378389A